HK Stock Market Move | CF PHARMTECH (02652) rose over 23% with ICF001 achieving full coverage of four major indications including IPF/PPF. Plans are simultaneously underway to commence Phase I clinical trials both domestically and internationally.

CF PHARMTECH (02652) surged over 23%, and as of the time of writing, it is up 12.03% at HKD 17.07, with a transaction volume of HKD 74.1826 million. In news, CF PHARMTECH announced that its self-developed long-acting inhaled dry powder candidate drug ICF001 has received implied permission from the National Medical Products Administration to conduct clinical trials for interstitial lung disease (specifically idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)). With this, ICF001 achieves full coverage for four major indications: PAH, PH-ILD, IPF, and PPF, aligning its product positioning with the global latest generation of long-acting inhaled prodrug development direction, thereby laying a solid regulatory foundation for the companys subsequent global multi-center clinical layout, registration strategy planning, and overseas strategic cooperation. ICF001 is a lung-targeted prodrug formulation, and its long-acting inhaled prodrug design logic shows significant advantages. The addition of these two new indication clinical studies will greatly enhance clinical value. In China, treatment for PAH has leaned towards multi-mechanism combination therapy; however, the supply of inhaled formulations and long-acting prodrug products remains limited, while there are still unmet clinical needs in the PH-ILD, IPF, and PPF fields. Additionally, the company plans to initiate Phase I clinical trials in China while simultaneously planning to launch Phase I clinical research both domestically and internationally, and will conduct clinical trials overseas upon obtaining the necessary approvals from the relevant foreign regulatory agencies.